DCOY private placement: initial ~$3.5M, up to ~$21M via milestone-tied warrant exercises
AI Summary
Decoy Therapeutics (DCOY) announced a private placement with a healthcare-focused institutional investor that could provide up to approximately $21M total: an expected initial closing of about $3.5M in gross proceeds and additional funding tied to milestone-based warrant exercises. Initial dilution will occur at the initial closing (≈$3.5M); further dilution is contingent on specified clinical and regulatory milestones (European CTA, UK Phase 2a approval, positive human challenge data) and related warrant issuance/exercise. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.
Positives
- Initial closing expected to provide roughly $3.5M in immediate gross proceeds
- Up to ~$21M total funding is milestone-linked, aligning additional capital to development progress
- Proceeds earmarked to advance the lead antiviral into clinical development
Negatives
- Up to ~$21M includes milestone-based warrant exercises that can be dilutive if triggered
- Timing and firm dates for the initial and subsequent closings are not specified
- Key economic terms (warrant strike prices, share/unit counts) were not disclosed, so exact dilution magnitude is unclear
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: after company starts sales
Dilution status
conditional
Dilution timing
Dilution status: Undetermined
Trigger type
purchase_trigger